Paperonium

Cancer immunotherapy · Cell Rep Med · 2026

Public plan’s main goal: tumor shrinkage. The paper’s main goal: safety. It never mentions the difference.

The public plan2022, never changedThe paper2026Main goalSecondary goalMissingTumor shrinkageat 24 monthsDose-limiting side effectsTumor shrinkageshrank in 2 of 17 assessedDose-limiting side effectsnot listed
The public plan2022, never changedThe paper2026Main goalSecondarygoalMissingTumorshrinkageat 24 monthsDose-limitingside effectsTumor shrinkageshrank in2 of 17 assessedDose-limiting side effectsnot listed

Each goal’s place in the trial’s public plan and in the paper

The paper says

In an early cancer trial, 25 people got their own immune cells, multiplied in a lab and injected inside the skull, plus a drug. The paper’s main goal: safety, measured as side effects serious enough to stop raising the dose. None were seen.

Its own data show

The public plan’s one main goal: tumor shrinkage at 24 months. The paper makes shrinkage secondary or exploratory and uses each patient’s best scan, not 24 months: tumors shrank enough to count in 2 of 17 assessed. Counting all 25, as the plan’s wording implies, gives 2 of 25 (8%), a figure the paper omits.

Trials post their main goal in a public registry so readers can check the paper reports the planned result. Safety as the main goal is normal for a first test in people. The problem: the paper never says its plan named another goal, and its summary leaves that goal’s result out, saying instead the disease seemed to hold steady.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Phase 1 study of intracranial T cell therapy with pemetrexed for refractory brain metastases and glioblastomas · Cell Rep Med (2026) · doi:10.1016/j.xcrm.2026.102967